Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457359 | 0.92 | CNR2 (0.67) | CNR2MAPTPOLBNPC1RAB9A | |
| SCHEMBL5454238 | 0.88 | CNR2 (0.53) | CNR2MAPTPOLBNPC1RAB9A | |
| SCHEMBL5447794 | 0.85 | CNR2 (0.63) | CNR2MAPTPOLBNPC1RAB9A | |
| SCHEMBL5457565 | 0.84 | CNR2 (0.70) | CNR2MAPTPOLBNPC1RAB9A | |
| SCHEMBL5077144 | 0.82 | CNR2 (0.81) | CNR2POLB | |
| SCHEMBL5787099 | 0.81 | CNR2 (0.71) | CNR2MAPTPOLBGLA | |
| SCHEMBL5213486 | 0.79 | CNR2 (0.58) | CNR2MAPTPOLBKDM4EL3MBTL1 | |
| SCHEMBL5466603 | 0.78 | CNR2 (0.60) | CNR2MAPTPOLB | |
| SCHEMBL5212098 | 0.78 | CNR2 (0.74) | CNR2 | |
| SCHEMBL5212581 | 0.77 | CNR2 (0.78) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562907-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | claimed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1562907-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885MAPT 2377/4885POLB 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.